yes, thats it, zero html write. Thank you for opening my eyes, maybe I should not have done that on a Friday evening :) Totally fixated on that tlsv1 alert I was...
regards from Berlin! Jens Neu Health Services Network Administration Phone: +49 (0) 30 68905-2412 Mail: jens....@biotronik.de Mladen Turk <mt...@apache.org> 01/15/2010 06:13 PM Please respond to "Tomcat Users List" <users@tomcat.apache.org> To Tomcat Users List <users@tomcat.apache.org> cc Subject Re: CVE-2009-3555 fix in tomcat-native-1.1.19?! On 01/15/2010 05:35 PM, Jens Neu wrote: > Dear all, > > > the GET / HTTP/1.0 until the "R" is manually inserted, I expect something > like > > <code> > 2860:error:1409444C:SSL routines:SSL3_READ_BYTES:tlsv1 alert no > renegotiation:./ ssl/s3_pkt.c:1053:SSL alert number 100 > </code> > > but certainly no RENEGOTIATION. Any hints? > Tomcat Native handles that like mod_ssl (actually I backported the mod_ssl code for that) by simply dropping the connection. I see you have 0 length write, so that's fine right? Regard -- ^TM --------------------------------------------------------------------- To unsubscribe, e-mail: users-unsubscr...@tomcat.apache.org For additional commands, e-mail: users-h...@tomcat.apache.org www.biotronik.com BIOTRONIK SE & Co. KG Woermannkehre 1, 12359 Berlin, Germany Sitz der Gesellschaft: Berlin, Registergericht: Berlin HRA 6501 Vertreten durch ihre Komplementärin: BIOTRONIK MT SE Sitz der Gesellschaft: Berlin, Registergericht: Berlin HRB 118866 B Vorsitzender des Verwaltungsrats: Dr. Max Schaldach Geschäftsführende Direktoren: Christoph Böhmer, Dr. Werner Braun, Dr. Lothar Krings BIOTRONIK - A global manufacturer of advanced Cardiac Rhythm Management systems and Vascular Intervention devices. Quality, innovation, and reliability define BIOTRONIK and our growing success. We are innovators of technologies like the first wireless remote monitoring system - Home Monitoring®, Closed Loop Stimulation and coveted lead solutions as well as state-of-the-art stents, balloons and guide wires for coronary and peripheral indications. We highly invest in the development of drug eluting devices and are leading the industry with our bioabsorbable metal stent program. This e-mail and the information it contains including attachments are confidential and meant only for use by the intended recipient(s); disclosure or copying is strictly prohibited. If you are not addressed, but in the possession of this e-mail, please notify the sender immediately and delete the document.
